@article{f576cce113d049a696723a1c06ff3e3f,
title = "Is there any role for the Hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?",
abstract = "The best therapy regimen for refractory obstetrical antiphospholipid syndrome remains to be determined. Additional treatments with steroids, plasma exchanges and immunoglobulins failed to show any beneficial effect. We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment. Furthermore, we highlighted that HCQ was able to dramatically reduce the antiphospholipid antibodies levels.",
keywords = "Hydroxychloroquine, obstetrical antiphospholipid syndrome, Hydroxychloroquine, obstetrical antiphospholipid syndrome",
author = "{De Carolis}, Sara and Angela Botta and {Di Pasquo}, Elvira and {Del Sordo}, Gelsomina and Antonio Lanzone and {De Carolis}, {Maria Pia}",
year = "2015",
doi = "10.1016/j.autrev.2015.04.010",
language = "English",
pages = "760--762",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL:
[email protected],
[email protected], INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010",
}